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Abstract
Background: Many patients with type 2 diabetes fail to achieve good glycaemic control. Poor control is associated
with complications including coronary heart disease (CHD). Effective self-management and engagement in health
behaviours can reduce risks of complications. However, patients often struggle to adopt and maintain these
behaviours. Self-management interventions have been found to be effective in improving glycaemic control. Recent
developments in the field of genetics mean that patients can be given personalised information about genetic-
and lifestyle-associated risk of developing CHD. Such information may increase patients’ motivation to engage in
self-management. The Coronary Risk in Diabetes (CoRDia) trial will compare the effectiveness of a self-management
intervention, with and without provision of personalised genetic- and lifestyle-associated risk information, with usual
care, on clinical and behavioural outcomes, the cognitive predictors of behaviour, and psychological wellbeing.
Methods/Design: Participants will be adults aged 25–74 years registered with general practices in the East of
England, diagnosed with type 2 diabetes, with no history of heart disease, and with a glycated haemoglobin level
of ≥6.45 % (47 mmol/mol). Consenting participants will be randomised to one of three arms: usual care control,
group self-management only, group self-management plus personalised genetic- and lifestyle-associated risk
information. The self-management groups will receive four weekly 2-hour group sessions, focusing on knowledge
and information sharing, problem solving, goal setting and action planning to promote medication adherence,
healthy eating, and physical activity. Primary outcomes are glycaemic control and CHD risk. Clinical data will be
collected from GP records, including HbA1c, weight, body mass index, blood pressure, and HDL and total
cholesterol. Self-reported health behaviours, including medication adherence, healthy eating and physical activity,
and cognitive outcomes will be assessed by questionnaire. Measures will be taken at baseline, 3 months
(questionnaire only), 6 months and 12 months post-baseline.
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Discussion: This study will determine whether the addition of personalised genetic- and lifestyle-associated CHD
risk information to a group self-management intervention improves diabetes control and CHD risk compared with
group self-management and usual care. Effectiveness of the combined intervention on health behaviours
cognitions theorised to predict them, and psychological outcomes will also be investigated.
Trial registration: This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786,
registered 28 June 2013.
Keywords: RCT protocol, Diabetes, Self-management, Genetic testing, Physical activity, Healthy eating, Medication
adherence, UKPDS
Background
Approximately 2.3 million people in the UK aged over
17 years have diagnosed diabetes, of which 90 % are di-
agnosed with type 2 [1]. This number is expected to rise
to 4 million by 2025 [2]. Complications in diabetes arise
from poor glycaemic control [3], and include renal dis-
ease, retinopathy, and peripheral vascular disease [1].
People with diabetes have two times the risk of develop-
ing coronary heart disease (CHD) compared with the
general population [1], and CHD is the cause of death in
52 % of people with diabetes [4]. Good glycaemic control
has, however, been found to be associated with reduc-
tions in the complications associated with diabetes and
the risk of developing CHD [3].
Glycaemic control and the health risks associated with
diabetes can be managed through appropriate self-
management behaviours including taking medication ap-
propriately, regular physical activity, following a healthy
diet and checking feet. These behaviours are also estab-
lished as important in the prevention of CHD risk in
people with and without diabetes. Therefore, interventions
to increase adherence to these behaviours in patients with
type 2 diabetes will have the dual benefit of reducing both
the risk of diabetes complications and CHD.
Many people with diabetes experience difficulties in
consistently carrying out the recommended behaviours.
To support patients with diabetes to achieve better gly-
caemic control, the Quality and Outcomes Framework
(QOF) recommends that all patients with diabetes are re-
ferred to group educational intervention within 9 months
of diagnosis [5]. In recognition that the provision of infor-
mation is insufficient to achieve the required behaviour
change, self-management interventions (SMIs) have been
developed and recognised as a key part of the delivery of
care for people with diabetes by the National Institute for
Health and Care Excellence (NICE) [6, 7].
SMIs for people with diabetes have been widely im-
plemented both in the UK and elsewhere. Systematic
and meta-analytic reviews indicate that they are ef-
fective in improving glycaemic control (glycated
haemoglobin (HbA1c) [8, 9]). However, few studies
have investigated the effect of SMIs on other
indicators of CHD risk, with the exception of body
mass index (BMI) [9]. A review of systematic reviews
of diabetes SMIs found that fewer than half of in-
cluded studies investigated outcomes associated with
CHD risk, such as blood pressure and lipid profile
[10], thus investigation of intervention effects on clin-
ical risk factors associated with CHD is warranted.
Reviews of the effect of SMIs for diabetes have indi-
cated that the most effective interventions are those that
target specific disease prevention behaviours such as
healthy eating and physical activity [9], and those that
use theory to specify the intervention components [11].
A systematic review has indicated that interventions
employing techniques from social learning theory (SLT)
[12, 13] such as modelling, increasing self-efficacy and
skills rehearsal were most effective for changing health
behaviours [11]. The University College London Dia-
betes Self-Management Programme (UCL-DSMP) [14]
is one such programme, based on SLT and employing
these techniques. Compared with standard care, this
intervention resulted in greater positive change in diet-
ary behaviours and physical activity, and showed a trend
towards significance in predicting greater improvements
in HbA1c after 3 months.
Evaluations of SMI interventions can be enhanced by
the measurement of their effects on the cognitive predic-
tors of health behaviour, described in theories of behav-
iour. Investigating the effect of an intervention on
cognitions can provide an explanation of intervention ef-
fects or null findings [15]. The Health Action Process
Approach (HAPA) [16] integrates several theories de-
scribing the predictors of health behaviour, and states
behavioural intention or motivation is a key determinant
of it. Antecedents of intention include perceived risks,
self-efficacy to perform, and expectancies about the out-
comes of the behaviour. Planning, social support, and
maintenance and recovery self-efficacy are specified as
post-intentional cognitions that predict behaviour. The
HAPA has been found to explain variance in intentions
and behaviour for several behaviours including healthy
eating in a healthy population [17], and physical activity
in patients with heart failure [18].
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Motivating engagement in self-management interventions:
personalised risk estimates
Increasing motivation to engage in and maintain self-
management behaviours may be one way to increase the
effect of SMIs on glycaemic control and engagement in
healthy behaviours. Current QOF guidance requires that
patients receive information about their lifestyle-
associated risk of CHD annually, using standardised risk
calculators e.g. the UK Prospective Diabetes Study
(UKPDS) [19]. It has been put forward that the salience
of this information about this modifiable risk may be in-
creased by providing it alongside information about
unmodifiable genetic risk of developing CHD [20].
Recent developments in the field of genetics have pro-
vided the opportunity to investigate the behavioural and
clinical effect of providing a personalised estimate of
both genetic- and lifestyle-associated risk of CHD. A
CHD genetic risk score based on 19 CHD risk loci has
been evaluated and found to have potential clinical util-
ity in addition to conventional risk factors in a group of
UK middle-aged healthy men [21]. This genetic risk
score can then be combined with a conventional risk
score from lifestyle risk calculators to give an overall es-
timate of 10-year CHD risk.
Currently there is no evidence to suggest individuals
will perceive engaging in risk-reducing behaviours to be
less beneficial should they receive a high risk result [22],
and evidence indicates that participants are not likely to
perceive genetics to be the sole cause of illness [23].
However, there is limited evidence that provision of per-
sonalised risk information alone will effect behaviour
change where support to change behaviour is not pro-
vided. A Cochrane Review [24] has identified a small
number of clinical trials in which behavioural effects of
genetic risk information have been examined, and found
no effect of receiving a test result on smoking cessation,
physical activity, taking medication and vitamin use. An
effect on dietary changes was found in only one study.
The review also found that while they aimed to change
behaviour, these studies did not report the use of add-
itional behaviour change techniques such as goal setting
or coping planning. However, there is some evidence for
an effect of receiving a genetic risk result on the cogni-
tions that predict behaviour; an effect of receiving a test
result on smoking cessation intentions was found for
analogue studies in which behavioural outcomes were
not investigated due to the absence of an available test.
Furthermore, receiving a risk result has been found to
predict change in other cognitions theorised to predict
behaviour in clinical and analogue studies, including fear
arousal, perceptions of risk of developing disease, and
perceived effectiveness of the target behaviour in redu-
cing risk. Further intervention may therefore be required
to help translate these cognitive changes into behaviour
change. Together these findings underline the potential
utility of investigating the behavioural and clinical effects
of providing personalised genetic- and lifestyle-associated
risk information in conjunction with an SMI.
Study aims
The Coronary Risk in Diabetes study (CoRDia) aims to
investigate the effect of an SMI with and without perso-
nalised genetic- and lifestyle-associated risk information,
compared with usual care. The primary outcomes are
glycaemic control measured as HbA1c, and percentage
CHD risk assessed using the UKPDS risk calculator.
Secondary outcomes are other indicators of CHD risk
including total and high-density lipoprotein (HDL) chol-
esterol, blood pressure, weight and BMI, and behaviours
including adherence to medication, diet and physical ac-
tivity. The effect of personalised risk information and
the SMI on the theory-based cognitive predictors of be-
haviour, quality of life, psychological wellbeing, and
emotional response to having a genetic test will also be
examined.
Methods/Design
A three-arm randomised controlled trial (RCT). Eligible
participants will be randomly allocated to either a group
self-management intervention (SMI), SMI plus risk results
(SMI + RR), or standard usual care. See Additional file 1
for the complete SPIRIT checklist.
Setting
The study will be conducted in GP surgeries and com-
munity diabetes clinics within the National Institute for
Health Research (NIHR) Eastern Clinical Research Net-
work (CRN). To maximise patient participation in this
study two models of recruitment and intervention deliv-
ery are proposed (i) standalone and (ii) hub and spoke.
Standalone practices will recruit participants from their
own patient lists and deliver the interventions in-house.
In the hub and spoke model, one practice will act as the
hub taking responsibility for recruitment and interven-
tion delivery for smaller local spoke practices that iden-
tify eligible patients from their patient lists.
Ethical approval and trial registration
Ethical approval for this study has been granted by the
East of England Research Ethics Committee (ref 12/EE/
0437). Local governance and assurances were issued by
Norfolk and Suffolk Primary and Community Care Re-
search Office, Cambridgeshire Community Services Na-
tional Health Service (NHS) Trust, and Essex and
Hertfordshire Comprehensive Local Research Network
(CLRN) Office. A Data Monitoring Committee will be
convened to review interim data and monitor safety and
overall conduct of the trial. This study has been
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registered at ClinicalTrials.gov; registration identifier
NCT01891786.
Recruitment
Primary care providers
The Eastern CRN will recruit suitable primary care pro-
viders. Participating GP surgeries or community diabetes
clinics must be research active and demonstrate ad-
equate numbers of eligible patients. Recruiting staff will
need to have received Good Clinical Practice (GCP)
training. Practices will be offered CRN research nurse
support where they do not have sufficient resources to
complete all study activities.
Patients
Patients diagnosed with type 2 diabetes who are regis-
tered at a GP surgery within the East of England, and
who are due an annual diabetes review within the re-
cruitment window will be invited to participate. Eligible
patients must be: aged between 25 and 74 years at the
time of recruitment, of White, Afro-Caribbean or Asian-
Indian ethnicity, be fluent in spoken English, and have had
an HbA1c of ≥6.45 % (47 mmol/mol) in the 6 months pre-
ceding recruitment. Patients will be excluded if they have:
history or diagnosis of ischaemic heart disease, transient
ischaemic attack (TIA) or peripheral vascular disease,
current serious or enduring mental health problems that
would prevent study participation, are currently undergo-
ing treatment for a life-threatening condition or are in the
terminal stages of a condition. Participants who do not fit
the ethnicity requirements will be excluded; this is because
the genetic test and a primary outcome measure (UKPDS
Risk Engine) have not been validated outside of the de-
scribed ethnic groups. Adults who cannot consent for
themselves will also be excluded.
Patients due their annual diabetes review within the 8-
week recruitment window will be assessed for eligibility
and invited to participate in the study via letter of invita-
tion or opportunistically at the time of an appointment.
Each practice will recruit between one and three cohorts
of 15 participants.
Eligible interested patients will be invited to a consent-
ing appointment where they will have the opportunity to
review the participant information sheet with the prac-
tice or research nurse and give written informed consent
to participate in the study. Once participants have com-
pleted baseline questionnaires they will be randomised
to study condition, see Fig. 1.
Randomisation and blinding
Participants will be randomised at the individual level
using randomly permuted blocks. The randomisation
sequence will be generated using a randomisation web-
site [25]. Blocks of 15 allocations will be generated with
a 1:1:1 ratio of study arm allocations to ensure a balance
of five participants per study arm for each cohort. Each
cohort of 15 participants will comprise patients recruited
from a single GP practice site, or a single hub and spoke
site grouping. Randomisation allocation will be con-
cealed in consecutively numbered opaque sealed enve-
lopes. As with all studies of this type it is not possible to
blind participants, the recruiting nurse, or intervention
facilitators to group allocation once the envelope has
been opened. The data will be analysed by a researcher
blinded to the allocation of the groups.
Study interventions
Self-management intervention
Participants allocated to the SMI group and the SMI +
RR group will attend group self-management sessions
for 4 consecutive weeks, which will be held at a local GP
surgery or community practice, in addition to their usual
care. Each session will last approximately 2 hours, and
will be facilitated by an SMI-trained practice or research
nurse with experience of providing clinical care to pa-
tients with diabetes, paired with a health psychologist re-
searcher or layperson. Ten participants will attend each
SMI group (five SMI only, five SMI + RR). The facilitator
will keep an attendance log. Intervention sessions will be
audio recorded where participants provide permission,
to investigate intervention fidelity.
All SMI facilitators will attend a 2-day self-management
training course led by two experienced self-management
practitioners and trainers. The training comprises teach-
ing regarding theories of behaviour change and self-
management. Facilitators will be taught how to use the SMI
manual and will practice skills for managing groups. After
training they will be supported to deliver the intervention
through pre- and post-session briefing meetings each week
within their facilitator pairings, and with the research team.
The SMI will be adapted from the UCL-DSMP [14]. See
Additional file 2 for sample excerpts from the CoRDia
SMI facilitator manual. For three of the four sessions the
group will address specific target behaviours: medication
adherence, healthy eating and physical activity respect-
ively. For the fourth session, participants will be invited to
identify additional target behaviours that they believe to
be important in managing diabetes and/or CHD risk (e.g.
foot care, smoking cessation). The following behaviour
change techniques [26] will be delivered in each session:
1. Knowledge and information sharing: Each session
will include brief didactic teaching to ensure that all
participants have a clear understanding of the
importance of, and how to manage, their diabetes in
relation to the target behaviour.
2. Problem solving: Participants will be asked to
brainstorm difficulties that they experience with
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\carrying out the target behaviour. Difficulties that
several members of the group are experiencing, or
would like to discuss, will be selected and strategies
to overcome them elicited from the group. Strategies
for several difficulties can be discussed, subject to
the requirements of the group.
3. Action planning: In the first session, the principles of
goal setting and action planning will be didactically
presented. At the end of each session participants will
be invited to set a goal and develop a detailed written
action plan for the following week, targeting the
behaviour in question. The action plan includes
information about the target behaviour, the frequency
and intensity with which it will be carried out, and any
plans they need to make to overcome anticipated
difficulties. Participants will rate their confidence to
carry out the behaviour on a scale of 1–10. Where
participants wish to (e.g. if they do not have difficulties
with taking medication), an alternative health
behaviour can be targeted. The facilitator will provide
support to write the action plan and then will model
reporting their personal action plan to the group. The
group will be invited to report their own.
4. Goal review and praise/reward: For the second
and subsequent sessions, goal review is carried out,
where participants report back to the group about
Fig. 1 Study flow
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their goal attempt. Where a goal has been partially
achieved or not achieved, strategies to overcome
experienced problems will be briefly brainstormed by the
group. Participants who have been successful or partially
successful in achieving their goal will be praised by the
facilitator and encouraged to recognise their success.
Risk results intervention
Participants allocated to the SMI + RR group will be asked
to review and sign the consent form specific to the genetic
test and provide a saliva sample for analysis using the Ora-
gene DNA Self-collection Kit (DNA Genotek Inc., Ontario,
Canada). Deoxyribonucleic acid (DNA) will be extracted
according to the manufacturer’s instructions and analysed
as described below. Participants will be invited to attend a
one-on-one appointment with the researcher in the week
prior to the first SMI group session, where a trained
researcher will present the results of the risk report to each
participant using a script to ensure consistency in delivery.
The risk report
Risk reports will be personalised to describe individual
CHD risk, defined as risk of having a myocardial infarction
(MI). There are three sections to the risk report, detailing (i)
genetic lifetime CHD risk presented as a graph, with the pa-
tient’s personal risk relative to average risk, (ii) 10-year life-
style CHD risk presented as a graph, reporting absolute and
relative risk to the average person’s percentage risk. This is
supported by text detailing the participant’s estimated life-
style risk, the risk for the average person of their age, ethnic
group and gender, and risk relative to the average person,
expressed as a percentage. (iii) Combined genetic and life-
style overall 10-year CHD risk presented in the same man-
ner as lifestyle risk. The report will state that it is possible to
reduce lifestyle risk by engaging in health behaviours e.g.,
eating more healthily and becoming more physically active,
all of which are addressed in the SMI. Participants will be
given their printed personalised risk report to keep for their
own records; copies of individual’s risk reports will not be
stored or made available to their care provider.
Genetic analysis and risk calculation
Genotypes for 19 CHD risk single nucleotide polymor-
phisms (SNPs) will be determined using the Randox Car-
diac Risk Prediction Array (Randox Laboratories Ltd.,
Crumlin, UK). In the event of any discrepancies, geno-
types will be confirmed by Sanger sequencing. The num-
ber of risk alleles for each SNP carried by an individual
will be multiplied by its reported meta-analysis effect size
for CHD, for method see [21] to give an individual’s gen-
etic risk score. To put the genetic risk score into context,
the individual genetic risk score will then be adjusted for
the population average genetic risk score. The population
average risk is calculated by multiplying the expected
frequency of the three genotypes (based on the allele fre-
quency determined in the source publications, see [21] for
each SNP by the number of risk alleles corresponding to
that genotype). These products are then summed for all
the SNPs. The comparative average person is someone
with type 2 diabetes of the same age, ethnicity and gender
as the individual participant, with the average systolic
blood pressure (BP) and lipid ratio determined using data
from the University College Diabetes and Cardiovascular
Study (UDACS) [27]; data presented in Additional file 3.
An appropriate value for HbA1c has been set on advice
from a group clinician. The 10-year lifestyle CHD risk will
be estimated using the UKPDS risk engine v2.0 [28]. To
give the combined 10-year CHD risk incorporating both
lifestyle and genetic risk the population-adjusted genetic
risk will be then added to the UKPDS risk.
Usual care control group
Those randomised to usual care will be advised to con-
tinue to manage their diabetes as they would normally.
Usual care will be documented across practices and
community services involved in the study using a check-
list informed by the General Medical Services QOF
2014/15 and NICE clinical guidelines for the manage-
ment of type 2 diabetes (modified March 2014). The
checklist will be developed in consultation with specialist
primary care diabetes staff.
Measures
Socio-demographic information
Age, ethnicity, marital status, and education and
employment status will be collected at baseline. Partici-
pants will also be asked to self-report whether they have
attended any health management programmes previ-
ously and to indicate if there is a known history of CHD
in their immediate family.
Primary outcomes
HbA1c. Change in blood glucose control as measured by
glycated haemoglobin (HbA1c) will be recorded from
patient’s medical records. HbA1c reflects average plasma
glucose concentration over an 8–12-week period and
will be collected at baseline and 6 and 12 months
post-baseline.
UKPDS risk. Ten-year risk of CHD defined as fatal,
and non-fatal, MI will also be calculated at baseline and
6 and 12 months post-baseline using the UKPDS risk
engine (v2.0) [28]. UKPDS is a risk calculator specifically
for people with type 2 diabetes. Percentage risk is calcu-
lated from participants’ age, years since diabetes diagnosis,
presence of atrial fibrillation, reported smoking behaviour,
sex, ethnicity, HbA1c, systolic BP, and total and HDL
cholesterol.
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Secondary outcomes
Clinical
The following clinical measures will also be recorded
from participant’s medical records at baseline, and 6 and
12 months post-baseline to be considered independently:
(i) sitting systolic and diastolic BP, (ii) total cholesterol,
(iii) HDL cholesterol, and (iv) BMI.
If available in patient records, the following additional
measures will also be recorded: (i) smoking status, (ii)
blood glucose fasting sample, (iii) low-density lipopro-
tein (LDL) cholesterol, (iv) triglycerides, (v) serum cre-
atinine, (vi) estimated glomerular filtration rate (eGFR),
(vii) urine albumin to creatinine ratio (urine ACR), (viii)
foot risk assessment, and (ix) impotence.
The following self-reported behavioural, cognitive and
psychological measures will be measured at baseline,
immediately post-intervention (approximately 3 months
post-baseline), and 6 months and 12 months post-
baseline.
Behavioural
The summaries of self-care activities measure will assess
diabetes self-management behaviours for diet, exer-
cise, blood sugar testing, smoking and diabetes medi-
cations [29].
Cognitive predictors of health behaviours
The cognitive predictors of behaviour described in the
HAPA will be assessed using measures adapted from
those used for the Risk Appraisal Consequences in
Korea Study [30]. Changes to wording have been made
to increase clarity in English. Measures assess:
1. Perceived risk of developing heart disease: The
following three scales assess perceived risk in
relation to six types of CHD: high cholesterol, heart
attack, high blood pressure, stroke, angina, heart
disease. Participants respond on a 7-point Likert
scale for each item.
a) Absolute risk assessing own perceived risk.
b) Absolute risk for average person with diabetes
assessing perceived risk of average person of same
age, gender, ethnic group.
c) Comparative risk of developing CHD assessing
perceived risk in comparison with average person
with diabetes.
2. Perceived severity of CHD: assessed for each of
the six types of CHD on a 7-point Likert scale for
(i) average person, and (ii) self.
3. Intentions to engage in each of the five target
behaviours: healthy eating, physical activity,
checking blood sugars (where prescribed), taking
medication, stopping smoking. Participants respond
on a 4-point Likert scale for each behaviour.
4. Planning with respect to five target behaviours: five
scales with up to 10 items assess plans for when,
where, what to do, how often and plans needed to
engage in each of the target health behaviours.
Responses are given on a 4-point Likert scale.
5. Outcome expectancies towards each of target
behaviours: assessed on five scales comprising
6–12 items, relating to potential positive
and negative outcomes of the target behaviour.
Participants respond on a 4-point Likert scale.
6. Self-efficacy to perform each of the five target
behaviours:
a) Confidence to perform the behaviour regularly:
five items relating to target behaviours.
Participants respond on a 10-point Likert scale.
b) Confidence to overcome barriers to target
behaviour: five scales relating to each target
behaviour. Each scale has 10–13 items relating
to problems that may be encountered.
Participants respond on a 10-point Likert scale.
Psychological outcomes
Depression and anxiety will be assessed using the Hos-
pital Anxiety and Depression Scale (HADS) [31] a 14-item
questionnaire for use in patients with physical health
problems. Total scores on each subscale are summed
(score range = 0–21), with higher scores indicating greater
levels of anxiety or depression. The HADS has demon-
strated good reliability and validity among primary care
patients [32].
Health-related quality of life will be assessed using the
Short-Form Health Survey (version 2) (SF-12v2), which
comprises two subscales: The Mental Component Score
(MCS) and the Physical Component Score (PCS), re-
flecting mental and physical health-related quality of life
respectively. Total scores range from 0–100 with higher
scores indicating greater health status. Both subscales
of the SF-12v2 have reported good reliability and val-
idity [33].
Response to risk results
For those in the SMI + RR group, participant responses
to receiving personalised risk information will be assessed
immediately post-intervention, and 6 and 12 months post-
baseline.
Recall and comprehension of risk results: Questions
will be developed for this study. Participants will be
asked to recall from memory their absolute lifestyle and
overall risk percentage, and to identify the description
relative to the average person of their genetic risk result
from a list of six statements. Comprehension of the
genetic test result will further be assessed by asking par-
ticipants to identify whether four descriptive statements
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about their result are true or false, e.g., ‘Your genetic test
result is based on the number of gene variants you have’.
Psychological impact of receiving a genetic and lifestyle
risk result: Will be assessed by adapting the Impact of
Genetic Testing for Alzheimer’s disease (IGT-AD) scale
[34] to make it appropriate to CHD risk. This measure
comprises distress and positive experiences subscales;
three questions will be eliminated from the distress
subscale as they are not relevant to this study. Responses
to this adapted 13-item measure will be recorded on a
5-point Likert scale, with higher scores indicating greater
psychological distress; responses to the positive experiences
subscale are reverse scored.
Power calculation
A clinically important change in HbA1c level of 12.5 %
(SD 15.5 %) was identified from a Health Technology
Assessment of blood glucose monitoring devices [35]
over a period of 18 months. This represents a reduction
in HbA1c (%) from 8 to 7 or from 9 to 7.9. As the current
study has a shorter follow-up, we base our sample size cal-
culations on a conservative change that would be clinically
achievable in this time frame: an HbA1c change of 6.25 %
representing a reduction from an HbA1c (%) of 8 to
7.5 or from 9 to 8.44 (this represents a change from
63.9 mmol/ml to 59.9 mmol/ml; and 74.9 mmol/ml to
69.4 mmol/ml).
The expected 6.25 % change in HbA1c (SD = 15 %)
represents an effect size of d = 0.40, a small to moderate
effect size (d = 0.2 – small, 0.5 – medium and 0.8 – large
effect); equivalent to effect size f = 0.2 in G*Power [36]
calculated for repeated measures, between-subjects ana-
lysis of variance (ANOVA) analyses. Based on the
current design (three groups, four measurement points),
alpha = 0.05, power = 80 %, f = 0.20 and a correlation be-
tween measurement points of 0.70, G*Power indicates a
total sample size of 192. With an expected attrition rate
of 20 %, a sample size of 240 (80 per study arm) will be
sought.
Analysis
Preliminary analyses
Descriptive statistics will be used to assess levels of miss-
ing data, the frequency of events, participant characteris-
tics, and the central tendency and dispersion of key
variables. If missing data analyses indicate large levels of
missing data (>10 % on any variable), multiple imput-
ation using SPSS Markov Chain Monte Carlo procedures
(IBM Corp., Armonk, NY, USA) will be implemented to
produce 10 imputed datasets. These will each be ana-
lysed as specified below; thereafter standard multiple im-
putation procedures will be used to combine the multiple
scalar and multivariate estimates quantities. If missing
data levels are lower, a single imputation procedure will be
implemented, followed by standard analyses procedures.
Main analyses
Spearman’s or Pearson’s correlations will determine rela-
tionships between variables and chi-squared analyses will
be used to compare rates data. For the main group dif-
ferences and time-based analyses, data will be analysed
using intention-to-treat principle and then repeated with
per protocol subsamples, for sensitivity analyses. For the
main continuous outcome measures (HbA1c and CHD
risk data) and secondary outcomes 3 x 3 mixed analysis
of covariance (ANCOVA) controlling for existing group
differences on key process variables will be conducted
for each outcome, with post hoc comparisons using
Sidak’s correction. Should the data meet the criteria for
multi-level modelling, these analyses will be conducted
in lieu of ANCOVA.
Discussion
Patients with type 2 diabetes frequently require support
to self-manage health behaviours such as medication ad-
herence, consuming a healthy diet, and engaging in
physical activity, which are known to reduce the risks as-
sociated with poor glycaemic control in diabetes, includ-
ing coronary heart disease. Motivation to engage in, and
the effectiveness of, a self-management intervention may
be increased by providing estimates of genetic- and
lifestyle-associated risk of CHD. This study will use a
novel genetic test to test the effects of an SMI with and
without personalised genetic- and lifestyle-associated
risk estimates on clinical indicators of diabetes and CHD
risk, health behaviours, cognitive predictors of behaviour
and psychological outcomes in a cohort of patients with
type 2 diabetes.
Trial status
Patient recruitment has been ongoing since December
2013 and is expected to end June 2015. Study completion
is estimated to be June 2016.
Additional files
Additional file 1: SPIRIT checklist CoRDia protocol. Completed SPIRIT
checklist relevant to the study protocol. (DOCX 59 kb)
Additional file 2: Sample excerpts from the CoRDia SMI. Selected
sample excerpts from the CoRDia SMI Facilitator Manual including
introductory material, problem solving, and action planning sections.
(PDF 905 kb)
Additional file 3: UDACS average person risk data. CoRDia
protocol. Data from the University College Diabetes and Cardiovascular
Study (UDACS): comparator average person risk factor data. Average
person risk factor data from the University College Diabetes and
Cardiovascular Study (UDACS) used to determine average person
comparator in intervention coronary heart disease risk reports.
(DOCX 22 kb)
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